 "With this, Alkem Lab joins peer firms like Sun Pharma, Lupin, and Zydus Cadila, who have launched various medicines to treat Covid-19 patients.")
Alkem Laboratories shares jumped as much as 4.5 per cent to quote at Rs 2,972.6 on the BSE after the company launched Favipiravir in India under the brand name 'Alfluenza' for the treatment of mild to moderate Covid-19 patients.
"The cases of Covid-19 is increasing significantly across the globe. India too is affected with around 50,000 new cases being added on a daily basis. In this backdrop, Alkem Laboratories has launched Favipiravir under the brand name 'Alfluenza' in India for the management of mild to moderate cases of Covid-19. Favipiravir is approved by DCGI (Drug Controller General of India) for restricted
